Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with or without low-dose interferon alfa-2a after sunitinib failure in metastatic renal cell carcinoma
2007-005083-28Phase 2Terminated
- Sponsor
- Bayer
- Start
- Dec 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing Sorafenib monotherapy with Sorafenib plus low-dose interferon alfa-2a (2 arms). Primary endpoint: Median progression-free survival. Started Dec 2007; status: terminated.
02
Drugs
sorafenibinterferon alfa-2a
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2007-005083-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005083-28.